Special Warning : אזהרת שימוש

4.4   Special warnings and precautions for use

This product should not be used interchangeably with other medicinal products containing argipressin with different expressions of strength.

Argipressin must not be administered as bolus for therapy of catecholamine refractory shock.

Argipressin may only be administered under close and continuous monitoring of hemodynamic and organ- specific parameters.

The therapy with argipressin should only be started if no sufficient perfusion pressure can be maintained despite adequate volume substitution and application of catecholaminergic vasopressors.

Argipressin should be used with special caution in patients with heart- or vascular diseases. The application of high argipressin doses for other indications has been reported to cause myocardial and gut ischaemia, myocardial and gut infarction and reduced perfusion of the extremities.

Argipressin may in rare cases cause water intoxication. The early signs of drowsiness, listlessness, and headaches should be recognised in time to prevent terminal coma and convulsions.
Argipressin should be used cautiously in the presence of epilepsy, migraine, asthma, heart failure, or any state in which a rapid increase of extracellular water may produce hazard for an already overburdened system.

This medicine contains less than 1 mmol sodium (23 mg) per ml that is to say essentially ‘sodium-free’.

Effects on Driving

4.7   Effects on ability to drive and use machines
No studies have been conducted to evaluate the influence on the ability to drive and use machines.